Premium
The clinical pharmacology of hexamethylmelamine: Phase I study
Author(s) -
Louis John,
Louis N. B.,
Linman J. W.,
Donnelly W. J.,
Isaacs B. L.,
Schwartz S. O.
Publication year - 1967
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196781part155
Subject(s) - discontinuation , medicine , adverse effect , renal function , drug , pharmacology , population , clinical pharmacology , environmental health
The human pharmacology for a new oncolytic agent, hexamethylmelamine, is described. The dose tolerated by 80 per cent of the population treated for 28 days was 10 mg. per kilogram per day. The principal adverse effects requiring discontinuation of therapy were gastroenteric and hematologic. Despite discontinuation of therapy, a latent effect associated with prolonged therapy was peripheral neuropathy, which was not reversible in some of the patients. No adverse drug effects on liver, renal, pulmonary, and cardiovascular function were observed.